Developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease
Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform
Antibodies against a novel transporter target for chronic inflammatory diseases
Biologic quantification provided at the benchtop using electrochemical detection
Bioprocess for scaling patient derived organoids for use in high throughput screening
Light activated chemotherapy platform for the treatment of early-stage mouth cancers
Extracellular vesicle platform developing novel therapeutics to regenerate tissue in autoimmune diseases